SCHEMBL6890621

SCHEMBL6890621

CCCCCCCCCCCCCCCCCCN(CCCCCCCCCCCCCCCCCC)[C@@H](CCC(N)=O)C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOD1 Q9Y239 2/20 0.57
KMT2A Q03164 3/20 0.42
SOAT1 P35610 2/20 0.42
MEN1 O00255 1/20 0.42
FAAH O00519 1/20 0.42
TP53 P04637 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C19 P33261 1/20 0.42
GRIK1 P39086 2/20 0.41
GRIK2 Q13002 2/20 0.41
GPR84 Q9NQS5 3/20 0.41
FFAR1 O14842 1/20 0.41
MAPT P10636 2/20 0.40
LCK P06239 1/20 0.40
PPARD Q03181 1/20 0.40
ZDHHC20 Q5W0Z9 1/20 0.40
ZDHHC2 Q9UIJ5 1/20 0.40
KDM4E B2RXH2 2/20 0.39
SLC1A2 P43004 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30985279 1.00 NOD1 (0.57) NOD1KMT2ASOAT1MEN1FAAH
SCHEMBL29245602 1.00 NOD1 (0.57) NOD1KMT2ASOAT1MEN1FAAH
SCHEMBL27812063 1.00 NOD1 (0.57) NOD1KMT2ASOAT1MEN1FAAH
SCHEMBL30255144 0.98 NOD1 (0.56) NOD1KMT2ASOAT1MEN1FAAH
SCHEMBL28050915 0.94 NOD1 (0.53) NOD1KMT2ASOAT1MEN1FAAH
SCHEMBL2120825 0.94 NOD1 (0.53) NOD1KMT2ASOAT1MEN1FAAH
SCHEMBL21373143 0.94 NOD1 (0.52) NOD1KMT2ASOAT1MEN1FAAH
SCHEMBL19873202 0.94 NOD1 (0.52) NOD1KMT2ASOAT1MEN1FAAH
SCHEMBL29245559 0.92 FAAH (0.58) NOD1KMT2ASOAT1MEN1FAAH
SCHEMBL10766310 0.90 NOD1 (0.46) NOD1KMT2ASOAT1MEN1FAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119604312-A Lipid compositions for in vivo delivery 生命技术公司 2025-03-11 CN disclosed
EP-0869937-A4 NOVEL AMIDE-BASED CATIONIC LIPIDS PROMEGA BIOSCIENCES INC (US) 2004-07-21 EP disclosed
US-6638529-B2 Lipid copound for use in the transfer macromolecules in cells GENTA INCORPORATED 2003-10-28 US disclosed
US-20020156237-A1 Novel amide-based cationic lipids PROMEGA BIOSCIENCES, INC. 2002-10-24 US disclosed
US-6339173-B1 FOR INTERFERING WITH PROTEIN EXPRESSION IN A CELL; USEFUL IN LIPID AGGREGATES FOR THE DELIVERY OF MACROMOLECULES INTO CELLS PROMEGA BIOSCIENCES, INC. 2002-01-15 US disclosed
US-6020526-A Amide-based cationic lipids GENTA, INCORPORATED (US) 2000-02-01 US disclosed
EP-0869937-A1 NOVEL AMIDE-BASED CATIONIC LIPIDS GENTA INCORPORATED (US) 1998-10-14 EP disclosed
WO-1997003939-A9 NOVEL AMIDE-BASED CATIONIC LIPIDS 1997-05-22 WO disclosed
WO-1997003939-A1 NOVEL AMIDE-BASED CATIONIC LIPIDS GENTA INCORPORATED (US) 1997-02-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020156237-A1 Novel amide-based cationic lipids CETP, SGMS1, CERT1 NOD1 1493/4885KMT2A 990/4885SOAT1 206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.